Takeda's Growth and Emerging Markets Business Unit Aims for Double-Digit Revenue Growth Through 2030

- Target in2030Fiscal Year Achievement1Trillion-yen revenue (approximately90$100 million^[2]）

- Strategy Balancing Regional Distribution and Focusing on Core Markets、14The global brand’s product portfolio and the first wave of peak value conversion from its R&D pipeline will drive double-digit growth in business revenue.

- Committed to improving drug accessibility for patients in emerging markets, addressing their unmet medical needs, and driving sustainable growth.

Osaka, Japan and Cambridge, Massachusetts, U.S., March 16, 2021 /PRNewswire/ -- On March 11, Takeda Pharmaceutical Company Limited (Tokyo Stock Exchange Code: 4502; New York Stock Exchange Code: TAK) ("Takeda") announced the strategic roadmap for its Growth & Emerging Markets (GEM) Business Unit. By fiscal year 2030, the GEM Business Unit aims to achieve revenues of JPY 1 trillion (approximately USD 9 billion), more than doubling its current revenue and delivering annual double-digit growth above the market average. This potential growth will primarily be driven by a strategy that balances geographic diversification with a focus on core markets, targeted investments in 14 highly innovative global brands, and the first wave of peak value conversion from its R&D pipeline.

Ricardo Marek, President of Takeda’s Growth and Emerging Markets Business Unit, stated: “Takeda Pharmaceutical Company Limited’s vision is to deliver long-term value for patients, society, and shareholders. Building on this foundation, we are further refining our regional strategy to better serve the healthcare needs of a regional market that encompasses 85% of the global population. As a mission-driven, patient-centric, and values-based company, our portfolio features innovation and scalable competitiveness. Furthermore, we benefit from a highly promising market environment and an execution team capable of delivering high-performance results. We are committed to achieving sustainable revenue growth and improving medicine accessibility, enabling more patients to benefit from our innovative therapies, thereby saving lives and transforming outcomes.”

Growth & Emerging Markets Business Unit: 95%^[3]revenue is derived from the company’s five core business areas. Therefore, Takeda Pharmaceutical Company Limited is confident that its Growth and Emerging Markets Business Unit will achieve growth targets exceeding market expectations in the region over the next decade. The emerging markets region encompasses a population of 6.5 billion, where unmet patient needs persist within Takeda’s core therapeutic areas. We believe that through our globally consistent “Access First” strategy, Takeda will seize significant growth opportunities in these markets.

Costa Saroukos, Chief Financial Officer of Takeda Pharmaceutical Company Limited, stated: “By aligning with our global focus-on-innovation strategy, emerging markets will become a major revenue source for Takeda over the next decade. Through targeted investments in our product portfolio and key markets, we anticipate that revenue growth from specialty care and innovative medicines within our Growth & Emerging Markets business unit will outpace the market average. We will expand our 14 global brands in this region and drive the launch of products from our first wave of value-transformation pipeline peaks.”

Takeda’s Growth and Emerging Markets Business Unit plans to continue expanding in high-growth markets such as Brazil, China, and India. Within Takeda’s core therapeutic focus areas, these markets are expected to provide a robust platform for the sustained growth of existing products as well as the first wave of upcoming value-transformation pipeline products. Notably, China is poised to become a key growth driver for Takeda both regionally and globally, with its compound annual growth rate (CAGR) projected to exceed 20% over the next five years.^[1]。

Furthermore, building on the existing product portfolio of the Growth and Emerging Markets Business Unit, Takeda’s innovative R&D engine will also bring potentially transformative therapies to the region. Among the pipeline products in the first wave of value transition peaks, Takeda’s dengue vaccine candidate (TAK-003) is expected to be utilized in addressing the 390 million annual dengue infections worldwide. The majority of the anticipated revenue from this vaccine will originate from the Growth and Emerging Markets Business Unit, making it a significant growth driver for the region.

To support sustainable growth in emerging markets, Takeda Pharmaceutical Company Limited is committed to helping patients maintain continuous access to innovative medicines. Relevant measures include strengthening local healthcare systems and optimizing the sustainability of commercial operations. In the recently released 2021 Access to Medicine Index (ATM Index), Takeda ranked first in the “Governance of Access” indicator, highlighting the company’s outstanding performance in strengthening public health systems and compliance.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical (Tokyo Stock Exchange Code: 4502(NYSE: TAK) is a Japan-headquartered, values-based, R&D-driven global biopharmaceutical company. Takeda is committed to translating scientific breakthroughs into highly innovative medicines that safeguard patients’ healthy lives and promising futures. Takeda focuses on drug development in four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare diseases—and makes targeted investments in plasma-derived therapies and vaccines. We remain dedicated to developing highly innovative medicines by pioneering novel treatment approaches and strengthening our collaborative R&D engine, thereby building a robust and diverse product pipeline that helps improve people’s lives. With employees in approximately 80 countries and regions, we work hand in hand with local healthcare partners to deliver health benefits to patients worldwide.

For more information, please visithttps://www.takeda.com

About Takeda's Growth and Emerging Markets Business Unit

Takeda’s global operations span four regions: Japan, the United States, Europe and Canada (EUCAN), and Growth and Emerging Markets (GEM). The regional headquarters for the Growth and Emerging Markets business unit is located in Singapore, with operations in nearly 50 countries and territories, including Brazil, China, and Russia. These three countries, along with three key operational hubs* in South America, the Middle East, and the Asia-Pacific region, constitute the strategic focus of the Growth and Emerging Markets business unit. This focus supports the company in achieving sustainable, profitable growth in the region through commercial activities, while better serving patients by fulfilling Takeda’s commitment to expanding global access to medicines.

*The three major regions of GEM include:
ICMEA – India, CIS (excluding Russia), Middle East, and Africa; regional hub located in Dubai, UAE
SAM – Southern Cone, Andean Region, and Mexico; Regional Hub Located in Buenos Aires, Argentina
APAC – Asia-Pacific, with its regional hub located in Singapore

HeavyTo Prompt 

For the purposes of this document, “press release” refers to this document, any oral statements, any question-and-answer sessions, and any written or oral materials discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) in relation to the contents of this press release. This press release (including any oral briefings and any related question-and-answer sessions) is not, and does not constitute, represent, or form part of, any offer to purchase, or any solicitation of an offer to buy, subscribe for, register, exchange, sell, or otherwise dispose of, any securities, nor is it part of any solicitation of votes or approvals in any jurisdiction. No shares may be offered to the public by virtue of this press release. No securities may be offered or sold in the United States unless registered under the U.S. Securities Act of 1933, as amended, or an exemption from such registration is available. This press release (together with any further information that may be provided to recipients) is provided solely for informational purposes and is not intended for use in evaluating any investment, acquisition, disposition, or any other transaction. Any failure to comply with the above restrictions may constitute a violation of applicable securities laws.

All companies held directly or indirectly by Takeda through investments are independent entities. In this press release, the term “Takeda” is sometimes used for convenience as a collective reference to Takeda and its subsidiaries. Similarly, terms such as “we” (in both subject and object forms) and “our” are used collectively to refer to the subsidiaries or to represent the company’s employees. These expressions are also used in contexts where they carry no substantive meaning and do not refer to any specific company or companies.

Forward-Looking Statements 

This press release and any materials distributed in connection herewith may contain forward-looking statements, beliefs, or opinions regarding Takeda’s future business, future state, and operating results, including Takeda’s estimates, forecasts, targets, and plans. Forward-looking statements often include, but are not limited to, words such as “target,” “plan,” “believe,” “hope,” “continue,” “anticipate,” “aim,” “intend,” “ensure,” “will,” “may,” “should,” “would,” “could,” “expect,” “estimate,” “project,” or similar expressions, or their negative forms. The forward-looking statements contained herein are based solely on Takeda’s estimates and assumptions as of the date of publication. Such forward-looking statements do not constitute any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties, and other factors, including but not limited to: economic conditions facing Takeda’s global operations, including the macroeconomic environments in Japan and the United States; competitive pressures and developments; changes in applicable laws and regulations; the success or failure of product development projects; decisions by regulatory authorities or the timing thereof; fluctuations in interest and exchange rates; claims or questions regarding the safety or efficacy of sold products or product candidates; the timing and impact of post-merger integration efforts for acquired companies; and the ability to divest assets non-core to Takeda’s operations and the timing of any such divestitures. All of these factors could cause Takeda’s actual results, performance, achievements, or financial position to differ materially from any future results, performance, achievements, or financial position expressed or implied by such forward-looking statements. For more information on the above and other factors that may affect Takeda’s results, performance, achievements, or financial position, please refer to “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and other reports, available on Takeda’s website.https://www.takeda.com/investors/reports/sec-filings/orwww.sec.gov. Takeda’s future results, performance achievements, or financial position may differ materially from those expressed or implied in the forward-looking statements. Recipients of this press release should not place undue reliance on any forward-looking statements. Takeda has no obligation to update any forward-looking statements contained in this press release or any other forward-looking statements it may issue, except as required by law or securities trading regulations. Past performance is not indicative of future results, and Takeda’s performance described in this press release neither represents nor constitutes an estimate, forecast, or projection of Takeda’s future performance.

Medical Statement

The products described in this press release may not be available for sale in all countries/regions, or may be marketed under different trademarks, with different indications, dosage forms, or dosages. Nothing in this press release should be construed as promotion, solicitation, or advertising for any prescription drugs (including those under development).

[1] Includes incremental revenue not adjusted for the probability of technical success (PTS), and does not represent “forecast” or “target” figures. PTS refers to the probability that a specific clinical trial/study will achieve success based on predefined endpoints, feasibility, and other factors, thereby obtaining regulatory approval.

[2] The exchange rate calculation standard is 1 USD = 111 JPY.

[3] Adjusted for divested assets; growth based on fiscal year 2019 baseline